Eight-year-old Jonah woke up one May morning with a swollen face and a toothache. He refused the pain medication that his mom, Geneva Reynolds, tried to give him. He didn’t sleep or eat and cried constantly. Within a few days, Reynolds became so desperate that she and her husband had to physically restrain Jonah, dumping…
By MIKE MAGEE What’s wrong in the social science realm of health? Consider for example the mental health crises affecting teens across the nation, or the sharp decline in relationships and child bearing in young adult men and women, or the attack on vaccine policy by the wayward Kennedy, or the attempted dismantling of ACA…
Discrete choice experiments quantify respondent preferences over different alternative treatments due to their attributes. DCE assume individuals are rational and do not pick dominated options (i.e., where one option is weakly better than another option across all attributes and strictly better than the option across at least one attribute). However, Johnson et al. (2019) finds…
Verily and Samsung are partnering to integrate data from Galaxy smartwatches into Verily’s Pre platform. The goal is to create an end-to-end system that pharma researchers can use to deploy wearable devices in studies, analyze patient data remotely and then interpret the results. The post Verily & Samsung Team Up to Bring Smartwatch Data into…
Eight Sleep’s $50 million raise was led by Tether Investments. In total, Eight Sleep has raised over $250 million, and this round brings the company’s valuation to $1.5 billion. The post Eight Sleep Raises $50M to Build Predictive AI for Sleep appeared first on MedCity News.
Keynote speakers at HIMSS26 stress that overcoming fear and strategically repositioning are essential for healthcare organizations to survive and thrive through future headwinds
The acquisition has an enterprise value of more than $830 million and will bring to UHS a network of roughly 6,000 licensed therapists.
GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concerns from U.S. and European regulators. The post Alfasigma Pays $300M for Rights to GSK Rare Liver…
ECG Management Consultants Partner Greg Silva discusses variety of ways academic health systems are integrating community physicians into their infrastructure
Healthcare AI in the U.S. has progressed to a point where traditional, HIPAA-style compliance alone is no longer adequate. The next phase of regulation and market expectation will require continuous, medical-grade AI governance, and companies that don’t adapt now will be left behind. The post HIPAA Was Built for an Analog Era, Healthcare AI Has…